VVOS · Insider Trading
Vivos Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by VVOS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Gregg C Johnson | Director | A | — | — |
| 2026-09-18 | Leonard J Sokolow | Director | A | +12,000 deriv. | — |
| 2026-09-18 | Ronald Kirk Huntsman | Chief Executive Officer | J | +85,910 | +$50.00K |
| 2026-08-26 | Bradford K. Amman | Principal Accounting Officer | A | +250,000 | +$102.50K |
| 2026-07-15 | Michael C Skaff | 10%+ Owner | Buy | +5,498,660 deriv. | — |
| 2026-04-02 | Michael C Skaff | 10%+ Owner | Buy | +2,707,250 | +$3.63M |
| 2024-11-27 | Bradford K. Amman | Chief Financial Officer | A | — | — |
| 2024-11-27 | Ronald Kirk Huntsman | Chief Executive Officer | A | — | — |
| 2024-06-28 | Ralph Elias Green | Director | A | +4,000 deriv. | — |
| 2024-06-28 | Anja B Krammer | Director | A | +4,000 deriv. | — |
| 2024-06-28 | Matthew Thompson | Director | A | +4,000 deriv. | — |
| 2024-06-28 | Mark F. Lindsay | Director | A | +4,000 deriv. | — |
| 2024-06-28 | Leonard J Sokolow | Director | A | +4,000 deriv. | — |
| 2024-06-28 | Ronald Kirk Huntsman | Chief Executive Officer | A | — | — |
| 2024-06-28 | Bradford K. Amman | Chief Financial Officer | A | — | — |
| 2023-06-20 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +14,000 | +$7.42K |
| 2023-06-20 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +15,021 | +$8.06K |
| 2023-06-15 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +10,000 | +$4.90K |
| 2022-12-28 | Leonard J Sokolow | Director | A | +30,000 deriv. | — |
| 2022-12-28 | Mark F. Lindsay | Director | A | +30,000 deriv. | — |
| 2022-12-28 | Ralph Elias Green | Director | A | +30,000 deriv. | — |
| 2022-12-28 | Matthew Thompson | Director | A | +30,000 deriv. | — |
| 2022-12-28 | Bradford K. Amman | Chief Financial Officer | A | +200,000 deriv. | — |
| 2022-12-28 | Anja B Krammer | Director | A | +30,000 deriv. | — |
| 2022-12-28 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +20,000 | +$10.00K |
| 2022-06-03 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +12,000 | +$23.56K |
| 2022-02-28 | Ronald Kirk Huntsman | Chief Executive Officer | A | +125,000 deriv. | — |
| 2022-02-28 | Bradford K. Amman | Chief Financial Officer | A | +50,000 deriv. | — |
| 2021-09-22 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +5,000 | +$21.55K |
| 2021-09-02 | Bradford K. Amman | Chief Financial Officer | A | — | — |
| 2021-08-18 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +5,000 | +$15.00K |
| 2021-08-10 | Mark F. Lindsay | Director | A | +30,000 deriv. | — |
| 2021-08-10 | Ralph Elias Green | Director | A | +30,000 deriv. | — |
| 2021-08-10 | Leonard J Sokolow | Director | A | +30,000 deriv. | — |
| 2021-08-10 | Matthew Thompson | Director | A | +30,000 deriv. | — |
| 2021-08-10 | Gurdev Dave Singh | Chief Medical Officer | A | — | — |
| 2021-08-10 | Anja B Krammer | Director | A | +30,000 deriv. | — |
| 2021-05-25 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +4,000 | +$21.52K |
| 2021-05-25 | Bradford K. Amman | Chief Financial Officer | Buy | +1,000 | +$5.29K |
| 2021-03-17 | Bradford K. Amman | Chief Financial Officer | A | — | — |
| 2020-12-28 | Bradford K. Amman | Chief Financial Officer | Buy | +1,000 | +$7.38K |
| 2020-12-23 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +1,000 | +$7.27K |
| 2020-12-14 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | +500 | +$4.25K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael C Skaff | 10%+ Owner | 1,044,777 | $155.57K |
| Bradford K. Amman | Principal Accounting Officer | 250,080 | $37.24K |
| Ronald Kirk Huntsman | Chief Executive Officer | 73,061 | $10.88K |
| Gregg C Johnson | Director | 3,997 | $595 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VVOS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.